Ublituximab et sclérose en plaques : efficacité et sécurité à 5 ans

from La biblio Neuro · host Dr Nicolas Landragin

Cette étude clinique évalue les effets à long terme de l'ublituximab, un anticorps monoclonal chez des patients atteints de sclérose en plaques récurrente.Cree BAC, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, et al. Five Years of Ublituximab in Multiple Sclerosis ULTIMATE I and II Open-Label Extension Study. JAMA Neurol. 2026Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Episode metadata supplied by the publisher feed · Published Feb 18, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Ublituximab et sclérose en plaques : efficacité et sécurité à 5 ans

0:00 9:43

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of La biblio Neuro?

This episode is 9 minutes long.

When was this La biblio Neuro episode published?

This episode was published on February 18, 2026.

Can I download this La biblio Neuro episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!